Today: 10 June 2026
Browse Category

CSE:NOVO.B 17 January 2026 - 20 March 2026

Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy

Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy

Novo Nordisk shares fell 1.5% in Copenhagen Thursday despite FDA approval of a higher-dose Wegovy shot. Shares stayed down as Eli Lilly released new obesity drug data and Reuters reported India’s semaglutide patent expiry will allow cheaper generics. Novo expects to launch the 7.2-mg Wegovy in the U.S. in April. Over 40 Indian drugmakers are preparing generic versions as prices are set to drop.
20 March 2026
··
Novo Nordisk Class B stock price: Wegovy pill scripts hit 26,000 as earnings week approaches

Novo Nordisk Class B stock price: Wegovy pill scripts hit 26,000 as earnings week approaches

Novo Nordisk Class B shares closed down 0.23% at 369.55 Danish kroner Friday, capping a 7.9% slide over five sessions. U.S. prescriptions for oral Wegovy reached 26,109 in the week ending Jan. 23, after 3,071 in the first four days post-launch. The company faces rising competition in China and awaits EU approval for its MASH drug. Quarterly results and 2026 outlook are due Feb. 4.
31 January 2026
···
Novo Nordisk stock drops in Copenhagen as Wegovy pill demand gets its first real test

Novo Nordisk stock drops in Copenhagen as Wegovy pill demand gets its first real test

Novo Nordisk B shares fell 2.8% Monday in Copenhagen, closing at 378.15 crowns as investors reacted to early U.S. prescription data for the new oral form of Wegovy. Around 4.7 million shares traded. U.S. prescriptions for oral Wegovy reached nearly 3,100 for the week ending Jan. 9, while overall Wegovy prescriptions dropped 11%. Full-year results are due Feb. 4.
19 January 2026
··
Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Novo Nordisk A/S Class B shares surged 6.5% to 388.9 Danish crowns Friday in Copenhagen after early U.S. prescription data for the new Wegovy pill surfaced and Britain approved a higher Wegovy dose for certain obesity patients. Trading volume reached 13.9 million shares. IQVIA data showed 3,071 U.S. retail prescriptions for the pill in its first four days, not counting online orders.
17 January 2026
··

Stock Market Today

  • Megaport ASX:MP1 Surges 8.7% on AI-Ready Storage Launch and A$827M Equity Raise
    June 10, 2026, 11:54 AM EDT. Megaport Limited (ASX:MP1) shares jumped 8.7% following the June 2026 launch of Megaport Storage, an AI-ready cloud storage solution integrated with its global network and Latitude.sh compute platform. The company also announced a substantial A$827.35 million rights offering to fund expansion into AI infrastructure, including four major U.S. deals. Megaport aims to build a fully integrated compute-network-storage stack for data-intensive workloads, requiring 38% annual revenue growth to reach projected A$670.5 million in revenue by 2029. This ambitious strategy raises risks related to heavy capital expenditure and equity dilution. Analysts remain divided on the long-term outlook, with fair value estimates ranging from a 6% downside to a potential 22% upside. Investors face a critical execution test to translate rapid growth into sustained profits amid increased financial commitments.

Latest articles

Euro Tech Holdings Shares Slip on High-Volume CLWT Ballast-Water Launch

Euro Tech Holdings Shares Slip on High-Volume CLWT Ballast-Water Launch

10 June 2026
Euro Tech Holdings’ CLWT shares plunged 11.7% to $1.13 on heavy volume after launching a mobile hybrid ballast-water treatment facility, but the company’s announcement lacked customer names, order values, pricing, or a European sales partner, leaving investors with more questions than answers as the stock’s move outpaced any disclosed commercial progress.
Ming Shing Group Holdings shares surge, then fall back after $110M graphene move raises dilution questions

Ming Shing Group Holdings shares surge, then fall back after $110M graphene move raises dilution questions

10 June 2026
Ming Shing Group Holdings shares soared to $5.54 before plunging to $1.74 after closing a $110 million acquisition of PMA Nano Carbon Tech, paid with convertible notes that could create over 111 million new shares at $0.99 each, raising dilution concerns as investors weigh the company’s pivot from construction to graphene technology amid management turnover and a June 16 vote on massively increasing authorized shares.
Go toTop